Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the year ended December 31, 2014 and provided an update on its product pipeline and corporate activities.
“We made significant progress in 2014 in a number of areas, including important advances in our clinical programs. Our deuterium chemistry platform continues to be highly productive, providing us with excellent opportunities to expand our pipeline of product candidates, as evidenced by deuterium-modified ivacaftor, our new clinical candidate for cystic fibrosis,” stated Roger Tung, Ph.D., President and Chief Executive Officer of Concert Pharmaceuticals.
Help employers find you! Check out all the jobs and post your resume.
“We made significant progress in 2014 in a number of areas, including important advances in our clinical programs. Our deuterium chemistry platform continues to be highly productive, providing us with excellent opportunities to expand our pipeline of product candidates, as evidenced by deuterium-modified ivacaftor, our new clinical candidate for cystic fibrosis,” stated Roger Tung, Ph.D., President and Chief Executive Officer of Concert Pharmaceuticals.
Help employers find you! Check out all the jobs and post your resume.
